<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141125">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01762683</url>
  </required_header>
  <id_info>
    <org_study_id>LIRUSSI-AOI-2011</org_study_id>
    <nct_id>NCT01762683</nct_id>
  </id_info>
  <brief_title>Influence of Preconceptional Obesity on the Myometrial Cells Differentiation Toward a Contractyl Phenotype</brief_title>
  <acronym>ObeDi</acronym>
  <official_title>Study of Role of Mononuclear Cells of Maternal Peripheric Blood in Human Myometrial Primar Cell Lines Differentiation Toward a Contratyl Phenotype: Influence of Preconceptional Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to improve the understanding of cellular mecanism involved in
      delivery disorders in obese women, first by characterizing the hyperplasia phenomenon of
      myometrail cells induced by inflammatory stimulation (Il-1B), then by studying the role of
      blood mononuclear cells, of leptine and of obese women sera to interfere with the transition
      of myometrial cells toward hyperplasia phenotype.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2012</start_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Measuring the expression level of markers (Gama actine, Desmine, Connexine-43, and Ocytocine receptor) by Westernblotting</measure>
    <time_frame>up to 2 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Demonstrate in vitro the capacity of a Il-1B stimulus to induce the differentiation of the myometrial cells toward a hyperplasia phenotype, and that the answer depends on whether this is cells from normal weight women or obese women before conception.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Pregnancy Complication</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Myometrium biopsy and blood samples</intervention_name>
    <description>The biopsy of myometrium is specially realised for the study in surgical unit after the release of the child, in women with normal pregnancy but necessitating a caesarean.
The blood samples are realised, specially for the study, either during the medical exam before the ceasarean or specifically for the study.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent signed

          -  Patient affiliated with a social security scheme

          -  Patient with normal pregnancy necessitating a cesarean for obstetrical reasons

          -  No obvious infectious context

        Exclusion Criteria:

          -  Obvious inflammatory or autoimmune diseases

          -  Suspected or confirmed infectious context, including virale infection VIH, VHC, VHB

          -  Coagulation disorders
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marc BARDOU, Pr</last_name>
    <phone>380-393-433</phone>
    <phone_ext>+33</phone_ext>
    <email>Marc.Bardou@u-bourgogne.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maternité du CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <state>Bourgogne</state>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc BARDOU, Pr</last_name>
      <phone>380-393-433</phone>
      <phone_ext>+33</phone_ext>
      <email>marc.bardou@u-bourgogne.fr</email>
    </contact>
    <contact_backup>
      <last_name>Isabelle LE RAY, Md</last_name>
      <phone>380-393-223</phone>
      <phone_ext>+33</phone_ext>
      <email>Isabelle.Le-Ray-Ferrieres@u-bourgogne.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Paul SAGOT, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 7, 2013</lastchanged_date>
  <firstreceived_date>May 31, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pregnancy</keyword>
  <keyword>obesity</keyword>
  <keyword>differentiation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Pregnancy Complications</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
